Top-Rated StocksTop-RatedNASDAQ:XNCR Xencor (XNCR) Stock Forecast, Price & News $27.69 +0.55 (+2.03%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$26.92▼$27.7050-Day Range$26.05▼$29.9052-Week Range$19.35▼$38.20Volume278,925 shsAverage Volume259,497 shsMarket Capitalization$1.67 billionP/E RatioN/ADividend YieldN/APrice Target$45.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Xencor MarketRank™ ForecastAnalyst RatingBuy3.09 Rating ScoreUpside/Downside63.7% Upside$45.33 Price TargetShort InterestBearish8.71% of Shares Sold ShortDividend StrengthN/ASustainability-2.24Upright™ Environmental ScoreNews Sentiment0.63Based on 3 Articles This WeekInsider TradingSelling Shares$607,254 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.99) to ($3.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector570th out of 983 stocksPharmaceutical Preparations Industry283rd out of 486 stocks 3.5 Analyst's Opinion Consensus RatingXencor has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.33, Xencor has a forecasted upside of 63.7% from its current price of $27.69.Amount of Analyst CoverageXencor has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.71% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.Change versus previous monthShort interest in Xencor has recently increased by 0.96%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Xencor is -2.24. Previous Next 2.6 News and Social Media Coverage News SentimentXencor has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Xencor this week, compared to 3 articles on an average week.Search Interest2 people have searched for XNCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $607,254.00 in company stock.Percentage Held by InsidersOnly 4.97% of the stock of Xencor is held by insiders.Percentage Held by Institutions98.99% of the stock of Xencor is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xencor are expected to decrease in the coming year, from ($2.99) to ($3.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -11.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -11.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xencor (NASDAQ:XNCR) StockXencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.Read More Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Stock News HeadlinesMay 30, 2023 | finance.yahoo.comXencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 CongressMay 25, 2023 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 22, 2023 | americanbankingnews.comBank of America Begins Coverage on Xencor (NASDAQ:XNCR)May 20, 2023 | americanbankingnews.comXencor (NASDAQ:XNCR) Now Covered by StockNews.comMay 19, 2023 | msn.comB of A Securities Initiates Coverage of Xencor (XNCR) with Buy RecommendationMay 19, 2023 | msn.comBank of America Initiates Xencor Coverage with Buy RatingMay 19, 2023 | msn.comXencor a buy at BofA on protein therapeuticsJune 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 17, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Xencor, Inc.'s FY2023 Earnings (NASDAQ:XNCR)May 17, 2023 | americanbankingnews.comXencor's (XNCR) "Overweight" Rating Reaffirmed at Cantor FitzgeraldMay 12, 2023 | americanbankingnews.comXencor (NASDAQ:XNCR) Price Target Lowered to $39.00 at GuggenheimMay 11, 2023 | americanbankingnews.comXencor, Inc. to Post Q2 2023 Earnings of ($0.70) Per Share, SVB Leerink Forecasts (NASDAQ:XNCR)May 11, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Xencor, Inc. Increased by Wedbush (NASDAQ:XNCR)May 10, 2023 | markets.businessinsider.comWedbush Sticks to Their Buy Rating for Xencor (XNCR)May 10, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About XencorMay 8, 2023 | seekingalpha.comXencor, Inc. (XNCR) Q1 2023 Earnings Call TranscriptMay 7, 2023 | americanbankingnews.comXencor (XNCR) Set to Announce Earnings on MondayMay 1, 2023 | finance.yahoo.comXencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023April 28, 2023 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Receives $46.13 Average PT from BrokeragesApril 26, 2023 | finance.yahoo.comXencor Appoints Nancy Valente, M.D., as Chief Development OfficerApril 17, 2023 | finance.yahoo.comXencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023April 3, 2023 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Receives $46.13 Consensus Target Price from BrokeragesMarch 14, 2023 | finance.yahoo.comXencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023March 14, 2023 | finance.yahoo.comStrength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?February 28, 2023 | finance.yahoo.comXencor, Inc. (NASDAQ:XNCR) Analysts Just Trimmed Their Revenue Forecasts By 13%February 25, 2023 | finance.yahoo.comXencor Full Year 2022 Earnings: EPS Beats ExpectationsSee More Headlines XNCR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XNCR Company Calendar Last Earnings5/08/2023Today6/03/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees254Year FoundedN/APrice Target and Rating Average Stock Price Forecast$45.33 High Stock Price Forecast$59.00 Low Stock Price Forecast$36.00 Forecasted Upside/Downside+63.7%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,180,000.00 Net Margins-142.32% Pretax Margin-141.63% Return on Equity-19.41% Return on Assets-16.73% Debt Debt-to-Equity RatioN/A Current Ratio9.68 Quick Ratio9.68 Sales & Book Value Annual Sales$98.05 million Price / Sales17.06 Cash FlowN/A Price / Cash FlowN/A Book Value$11.32 per share Price / Book2.45Miscellaneous Outstanding Shares60,391,000Free Float57,390,000Market Cap$1.67 billion OptionableOptionable Beta0.76 Key ExecutivesBassil I. DahiyatPresident, Chief Executive Officer & DirectorJohn J. KuchChief Financial Officer & Senior Vice PresidentJohn R. DesjarlaisChief Scientific Officer & Executive VP-ResearchNancy ValenteChief Development Officer & Executive VPCelia E. EckertSecretary, Senior Vice President & General CounselKey CompetitorsChinook TherapeuticsNASDAQ:KDNYVerona PharmaNASDAQ:VRNAAmylyx PharmaceuticalsNASDAQ:AMLXIronwood PharmaceuticalsNASDAQ:IRWDRocket PharmaceuticalsNASDAQ:RCKTView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,536 shares on 5/26/2023Ownership: 0.021%Ameriprise Financial Inc.Sold 7,092 shares on 5/22/2023Ownership: 0.641%Putnam Investments LLCSold 14,078 shares on 5/22/2023Ownership: 0.215%JPMorgan Chase & Co.Bought 4,565 shares on 5/18/2023Ownership: 0.789%New York State Common Retirement FundSold 10,266 shares on 5/18/2023Ownership: 0.072%View All Insider TransactionsView All Institutional Transactions XNCR Stock - Frequently Asked Questions Should I buy or sell Xencor stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XNCR shares. View XNCR analyst ratings or view top-rated stocks. What is Xencor's stock price forecast for 2023? 11 brokers have issued 1 year price targets for Xencor's stock. Their XNCR share price forecasts range from $36.00 to $59.00. On average, they anticipate the company's share price to reach $45.33 in the next year. This suggests a possible upside of 63.7% from the stock's current price. View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts. How have XNCR shares performed in 2023? Xencor's stock was trading at $26.04 at the beginning of the year. Since then, XNCR shares have increased by 6.3% and is now trading at $27.69. View the best growth stocks for 2023 here. When is Xencor's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our XNCR earnings forecast. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) posted its earnings results on Monday, May, 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.27. The biopharmaceutical company had revenue of $18.90 million for the quarter, compared to analysts' expectations of $26.89 million. Xencor had a negative net margin of 142.32% and a negative trailing twelve-month return on equity of 19.41%. The firm's revenue was down 77.9% compared to the same quarter last year. During the same period last year, the business posted $0.39 EPS. What ETFs hold Xencor's stock? ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Raymond James SB-1 Equity ETF (RYJ) and Principal Healthcare Innovators ETF (BTEC). What is Bassil I. Dahiyat's approval rating as Xencor's CEO? 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN). What is Xencor's stock symbol? Xencor trades on the NASDAQ under the ticker symbol "XNCR." Who are Xencor's major shareholders? Xencor's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.43%), FMR LLC (6.22%), Price T Rowe Associates Inc. MD (5.45%), State Street Corp (5.43%), Dimensional Fund Advisors LP (2.56%) and Geode Capital Management LLC (1.92%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert and John J Kuch. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xencor's stock price today? One share of XNCR stock can currently be purchased for approximately $27.69. How much money does Xencor make? Xencor (NASDAQ:XNCR) has a market capitalization of $1.67 billion and generates $98.05 million in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. How many employees does Xencor have? The company employs 254 workers across the globe. How can I contact Xencor? Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350. This page (NASDAQ:XNCR) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.